Littleton, CO (June 29th, 2011) – Novus Biologicals, an international supplier of antibodies and antibody-related products to bioscience researchers, is proud to announce the opening of their second international office in Oakville, Ontario, Canada. Novus’ other offices include Novus Europe, which services Europe from Cambridge, United Kingdom, and the worldwide headquarters, based in Littleton, Colorado.
According to Invest in Canada, the Canadian biopharmaceutical market is currently valued at approximately $19 Billion. The opening of Novus Canada allows Novus Biologicals to capitalize on this market potential and serve the growing demand in the biopharma industry.
“Canada has remarkably talented research scientists who are making significant contributions towards global scientific advancement. By opening an office in Canada, we are proud to service the Canadian scientific community with antibodies and associated reagents more quickly than ever before,” says Wendy Starr, Divisional Manager of Novus’ Canadian operation. “Our expansion into Canada shows our continuing commitment to support biological and scientific research worldwide, and is a natural progression that follows on the heels of the successful launch of Novus Europe”.
With the opening of the new office in Ontario, Canadian researchers will now be able to receive Novus products more quickly and cost effectively with pricing in Canadian dollars. Novus Canada customers may also receive customer service and technical support in both English and French.
To contact Novus Canada, please email email@example.com or call 855-NOVUS-CA.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. The Novus Guarantee + Innovator’s Reward™ Policy 100% guarantees all of Novus’ products to work in the species and applications listed on the datasheet. Novus is a privately held company backed by Mainsail Partners (www.mainsailpartners.com), a San Francisco based private equity firm that invested in Novus in 2008. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
Nehal Saleh, PhD
Novus Biologicals Europe
12 Cambridge Science Park
Cambridge, CB4 0FQ, UK
Tel: +44 (0)1223 426001
Fax: +44 (0)871 971 1635
Novus Biologicals Worldwide
PO Box 802
Littleton, CO 80160 USA